Profile picture of Progenics Pharmaceuticals

Progenics Pharmaceuticals

Tarrytown, NY
2 staff members
2.5 432 Reviews
Company Profile

Progenics Pharmaceuticals is taking a proactive approach to fighting serious diseases. The company develops biotech drugs with oncology and virology applications, as well as therapeutics used in clinical care settings. Progenics' commercial product Relistor, which blocks the side effects of opioids without lessening their pain-killing power, is approved as an injectable treatment for opioid-induced constipation (OIC) in terminally ill patients. The drug was developed in collaboration with Wyeth Pharmaceuticals (now part of Pfizer). Also in the firm's pipeline are a therapeutic vaccine for prostate cancer, as well as a monoclonal antibody for treating HIV.

Company size

51 to 200

Type

Company - Public (PGNX)

Revenue

$50 to $100 million (USD) per year

Industry

Biotech & Pharmaceuticals

Competitors

Unknown

Founded

1986

Staff Members
avatar
CEO
1.0
Worked since Wednesday, Jun 19 2024
People Also Viewed